Evidence map›Paper›PMID 38787171›Full record

ReviewVeterinary sciences2024

Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.

Heike Aupperle-Lellbach, Alexandra Kehl, Simone de Brot, Louise van der Weyden

Abstract readReview
In one paragraph

Review in Veterinary sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Expression of MutatedVeterinary sciences · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Heike Aupperle-LellbachLaboklin GmbH&Co.KG, Steubenstr. 4, 97688 Bad Kissingen, Germany.ORCID 0000-0002-4601-1480
Alexandra KehlLaboklin GmbH&Co.KG, Steubenstr. 4, 97688 Bad Kissingen, Germany.ORCID 0000-0002-1547-0713
Simone de BrotInstitute of Animal Pathology, COMPATH, University of Bern, 3012 Bern, Switzerland.
Louise van der WeydenWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.ORCID 0000-0002-0645-1879

Funding

CVS (UK) Ltd N/AEveryCat Health Foundation EC22-021Kennel Club Charitable Trust N/A
6 · The paper itself

Abstract

Molecular biomarkers are central to personalised medicine for human cancer patients. It is gaining traction as part of standard veterinary clinical practice for dogs and cats with cancer. Molecular biomarkers can be somatic or germline genomic alterations and can be ascertained from tissues or body fluids using various techniques. This review discusses how these genomic alterations can be determined and the findings used in clinical settings as diagnostic, prognostic, predictive, and screening biomarkers. We showcase the somatic and germline genomic alterations currently available to date for testing dogs and cats in a clinical setting, discussing their utility in each biomarker class. We also look at some emerging molecular biomarkers that are promising for clinical use. Finally, we discuss the hurdles that need to be overcome in going 'bench to bedside', i.e., the translation from discovery of genomic alterations to adoption by veterinary clinicians. As we understand more of the genomics underlying canine and feline tumours, molecular biomarkers will undoubtedly become a mainstay in delivering precision veterinary care to dogs and cats with cancer.

Indexed as

catdiagnosticdoggeneticgermlinemutationpredictiveprognosticsomatictumour

Identifiers

PMID38787171
PMCPMC11126050

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.